Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade

Immune checkpoint blockade (ICB) has significantly improved the prognosis of cancer patients, but the majority experience limited benefit, evidencing the need for new therapeutic approaches. Upregulation of sialic acid-containing glycans, termed hypersialylation, is a common feature of cancer-associated glycosylation, driving disease progression and immune escape via the engagement of Siglec-receptors on tumor-infiltrating immune cells. Here, we show that tumor sialylation correlates with distinct immune states and reduced survival in human cancers. The targeted removal of Siglec-ligands in the tumor microenvironment, using an antibody-sialidase conjugate, enhances anti-tumor immunity and halts tumor progression in several mouse tumor models. Using single-cell RNA sequencing, we reveal desialylation mechanistically to repolarize tumor-associated macrophages (TAMs) and identify Siglec-E on TAMs as the main receptor for hypersialylation. Finally, we show genetic and therapeutic desialylation, as well as loss of Siglec- E, to synergize with ICB. Thus, therapeutic desialylation represents a novel immunotherapeutic approach, shaping macrophage phenotypes and augmenting the adaptive anti-tumor immune response.

Moleculary imprinted micro- and nanoparticles for cancer associated glycan motifs

Sialic acids are an important family of monosaccharides that are typically found as terminal moieties of glycans. Aberrant sialylation has been proven to correlate with various diseases including cancer. Glycosylation analysis is complex due to high diversityof the glycan isomers and their low abundance. Antibodies and lectins are commonly used in glycan purification and enrichment. However, high cost, poor availability, and limitation in storage/testing conditions hinders their application on a broader scale. This thesis is focused on the development of alternative glycan specific receptors with their potential applications in glycomics and cell imaging. The underlying technique for producing the synthetic receptors is molecular imprinting. Highly complementary binding sites are formed by fixing pre-ordered template/functional monomer complexes into a highly crosslinked polymer matrix. Fundamental investigation of this intermolecular imprinting approach in the imprinting of glycosylated targets is reported here. The core of this study focuses on the elucidation of relative contribution of orthogonally interacting functional monomers, their structural tuning and the importance of monomer, solvent and counterion choice on the imprinting. Molecularly imprinted polymers (MIPs) are developed as particles of different sizes for glycan/glycopeptide enrichment applications or combined with fluorescent reportergroups for use as glycan imaging nanolabels. Special attention is given to the improvement of sialic acid MIP selectivities toward particular structures associated with cancer biomarkers. Development of MIPs against such complex targets includes design of linkage selective MIPs with comprehensive studies of the affinities and selectivities of the final glycan specific materials.

Early steps in the biosynthesis of MUC2 epithelial mucin in colon cancer cells

Expression of the MUC2 mucin has been demonstrated in normal gastrointestinal and respiratory epithelium and in carcinomas of the gastrointestinal and respiratory tracts, breast, ovary, and bladder using RNA probes and (or) monoclonal antibodies reactive with peptide epitopes on the 23 amino acid tandem repeat. Mouse monoclonal antibodies 4F1 and 3A2 were previously obtained by immunization with mucin derived from the LS174T colon cancer cell line and a KLH conjugate of a synthetic MUC2 VNTR peptide. These antibodies react with distinct epitopes on synthetic VNTR peptides and with normal and malignant epithelial tissues. In the present study, we examined the biosynthesis of MUC2 in LS174T colon cancer cells, using these antibodies to immunoprecipitate labelled mucin. A very high molecular mass protein was immunoprecipitated following 1 min pulse labelling with [3H]threonine and [3H]proline. A slight increase in molecular mass was observed over the next 16 min; however, unlike the MUC1 mucin, there was no large difference in apparent molecular mass between the MUC2 protein precursor and fully processed mucin using separation by SDS–PAGE. O-Glycosylation began within 1 h of synthesis of the protein core. Mucin secretion into the culture medium was detected in the 2nd hour following synthesis and was largely completed within 4 h of synthesis. Secreted mucin was far less reactive with these monoclonal antibodies than the precursor protein.Key words: mucin, MUC2, biosynthesis, colon, cancer, glycosylation.